Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Grifols Biologicals Inc.
Sponsor:
Information provided by (Responsible Party):
Grifols Biologicals Inc.
ClinicalTrials.gov Identifier:
NCT01731938
First received: November 19, 2012
Last updated: June 25, 2014
Last verified: June 2014
  Purpose

This study is designed to assess the safety and efficacy of fibrin sealant (FS) Grifols in patients undergoing elective (non-emergency) soft tissue open surgery where bleeding may be present. The purpose of this study is to demonstrate that FS Grifols is not inferior to commercially-available oxidized cellulose pads (Surgicel®) in providing benefit in the time to hemostasis (i.e, the stoppage of bleeding). This study has a Preliminary Part (I) for study teams to become familiar with the application of FS Grifols and a Primary Part (II) to assess the safety and efficacy of FS Grifols. In both parts of the study, patients will be randomized in a 1:1 ratio to either FS Grifols or Surgicel.


Condition Intervention Phase
Soft Tissue Surgical Bleeding
Biological: Fibrin Sealant (FS) Grifols
Device: Surgicel®
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Soft Tissue Open Surgeries

Resource links provided by NLM:


Further study details as provided by Grifols Biologicals Inc.:

Primary Outcome Measures:
  • Proportion of subjects achieving hemostasis within four minutes after treatment start [ Time Frame: From start of treatment until 4 minutes after treatment start ] [ Designated as safety issue: No ]
    Subjects achieving hemostasis at the target bleeding site within 4 minutes following the start of treatment without the occurrence of re-bleeding until the completion of surgical closure.


Estimated Enrollment: 368
Study Start Date: November 2012
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fibrin Sealant (FS) Grifols
Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
Biological: Fibrin Sealant (FS) Grifols
Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.
Active Comparator: Surgicel®
Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
Device: Surgicel®
Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
Other Names:
  • Fibrillar absorbable hemostat
  • Oxidized regenerated cellulose hemostat

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hemoglobin (Hgb) ≥ 9.0 g/dL at Baseline (within 24 hours prior to surgical procedure).
  • Require elective (non-emergency), open (non-laparoscopic)surgical procedure involving soft (non-parenchymous) tissue.
  • Target bleeding site is identified on soft tissue during urologic, gynecologic or general surgery procedures: 1) Simple or radical nephrectomies, 2) Total adrenalectomies, 3) Radical prostatectomies, 4) Pyeloplasties, 5) Radical cystectomies, 6) Simple or radical hysterectomies, 7) Lymphadenectomies (in the retroperitoneal or pelvic region only), 8) Retroperitoneal tumor resections, 9) Mastopexies, and 10) Abdominoplasties.
  • A target bleeding site can be identified.
  • Target bleeding site has moderate bleeding according to the Investigator's judgment.

Exclusion Criteria:

  • Require thoracic, abdominal, retroperitoneal or pelvic surgery due to trauma.
  • Infection in the anatomic surgical area.
  • History of severe (e.g. anaphylactic) reactions to blood or to any blood-derived product.
  • Previous known sensitivity to any FS Grifols component or any Surgicel® component.
  • Females who are pregnant or nursing a child at Baseline (within 24 hours prior to surgical procedure).
  • Receiving an organ transplant during the same surgical procedure.
  • Undergone a therapeutic surgical procedure within 30 days from the screening visit.
  • A target bleeding site cannot be identified.
  • The target bleeding site has a mild or severe bleeding.
  • Occurrence of major intraoperative complications that require resuscitation or deviation from the planned surgical procedure.
  • Application of any topical haemostatic material on the cut soft tissue surface identified as the target bleeding site prior to application of the study treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01731938

Contacts
Contact: Paul Pinciaro, PhD paul.pinciaro@grifols.com

Locations
United States, Alabama
407 Recruiting
Florence, Alabama, United States, 35630
United States, California
320, 322, 323 Recruiting
Pasadena, California, United States, 91105
United States, Connecticut
404 Recruiting
Bridgeport, Connecticut, United States, 06606
United States, Florida
321 Recruiting
Boynton Beach, Florida, United States, 33472
United States, Minnesota
312 Recruiting
Rochester, Minnesota, United States, 55905
United States, Missouri
300 Recruiting
Saint Louis, Missouri, United States, 63110
United States, New York
327 Recruiting
Albany, New York, United States, 12208
305 Recruiting
New York, New York, United States, 10016
332 Recruiting
Poughkeepsie, New York, United States, 12601
United States, North Carolina
304 Recruiting
Winston Salem, North Carolina, United States, 27157
United States, Ohio
315 Recruiting
Cleveland, Ohio, United States, 44106
United States, Pennsylvania
400 Withdrawn
Hershey, Pennsylvania, United States, 17033
307 Recruiting
Pittsburg, Pennsylvania, United States, 15224
United States, South Carolina
325 Recruiting
Charleston, South Carolina, United States, 29425
United States, Tennessee
314 Recruiting
Memphis, Tennessee, United States, 38613
United States, Texas
324 Recruiting
Fortworth, Texas, United States, 76104
316 Recruiting
Houston, Texas, United States, 77024
United States, Washington
405 Recruiting
Tacoma, Washington, United States, 98431
Sponsors and Collaborators
Grifols Biologicals Inc.
  More Information

No publications provided

Responsible Party: Grifols Biologicals Inc.
ClinicalTrials.gov Identifier: NCT01731938     History of Changes
Other Study ID Numbers: IG1103
Study First Received: November 19, 2012
Last Updated: June 25, 2014
Health Authority: United States: Food and Drug Administration
Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines
Hungary: National Institute of Pharmacy
Serbia: Medicines and Medical Devices Agency

Keywords provided by Grifols Biologicals Inc.:
Fibrin Sealant
Soft tissue open surgery
Oxidized cellulose pads

Additional relevant MeSH terms:
Fibrin Tissue Adhesive
Hemostatics
Coagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 22, 2014